KISUNLA
KISUNLA (Donanemab-azbt) is an FDA-approved monoclonal antibody therapy designed for the treatment of early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia stages. Each single-dose 20 mL vial contains Donanemab-azbt, a humanized antibody that targets amyloid beta plaques in the brain—one of the key pathological hallmarks of Alzheimer’s disease.
By promoting the clearance of amyloid deposits, KISUNLA helps slow the progression of cognitive and functional decline, offering new hope for patients and families affected by Alzheimer’s. The medication is administered intravenously (IV) under the supervision of a qualified healthcare professional, typically once every four weeks.
At InfusionMed USA, located in Carrollton, Texas, we provide reliable access to KISUNLA for clinics, hospitals, and infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding areas — ensuring safe, timely, and compliant delivery for Alzheimer’s care providers.
For IV infusion use only. Store at 2°C–8°C (36°F–46°F). Do not freeze.
Download Form